Abstract:Background. In the paediatric liver transplant programme in Johannesburg, South Africa (SA), tacrolimus is the calcineurin inhibitor of choice, comprising an essential component of the immunosuppression regimen. It is characterised by a narrow therapeutic index and wide interpatient variability, necessitating therapeutic drug monitoring of whole-blood concentrations. Pharmacogenetic research, although not representative of SA population groups, suggests that single-nucleotide polymorphisms within the cytochrome P450 3A5 (CYP3A5) gene contribute to the variability in tacrolimus dosing requirements. The rs776746 polymorphism, CYP3A5*3, results in a splice defect and a non-functional enzyme. Clinically, to reach the same tacrolimus concentration-to-dose ratio (CDR), expressors (CYP3A5*1/*1 and *1/*3) require a higher tacrolimus dose than non-expressors (*3/*3). Objectives. To compare the pharmacokinetics of tacrolimus in paediatric liver transplant recipients with their donors’ CYP3A5 genotypes, considering both donor and recipient characteristics. Methods. Blood samples from 46 living liver donors were collected, their genomic DNA was extracted, and their CYP3A5 genotype was established (polymerase chain reaction and restriction fragment length polymorphism analysis, validated by Sanger sequencing). The relationship of donor and recipient characteristics with the mean tacrolimus CDR was analysed using a general linear model. Non- confounding significant variables were included in a multiple regression model. Results. The study showed that all expressor donors genotyped as CYP3A5*1/*1 were of black African self-reported race and ethnicity. During the first 15 days post-transplant, we found that children who received grafts from donor CYP3A5 expressors (CYP3A5*1/*1 and *1/*3) had significantly lower mean tacrolimus CDRs compared with those who received grafts from donor CYP3A5 non-expressors (*3/*3); the recipients of CYP3A5 expressor grafts therefore require higher doses of oral tacrolimus to achieve the same therapeutic target range. In addition, graft-to-recipient weight ratio and the CYP3A5 donor genotypes were independent factors that significantly (p<0.05) affected mean tacrolimus CDRs in recipients. Conclusion. In this study, we showed that all CYP3A5*1 homozygote donors were of black African self-reported race and ethnicity, and tacrolimus CDRs in paediatric living-donor liver transplant recipients were significantly affected by donor graft size and donor CYP3A5 genotypes. Information from this study may inform the development of an Afrocentric tacrolimus precision-medicine algorithm to optimise recipient safety and graft outcomes.

Impact of CYP3A5 Genotype of Recipients and Donors on Tacrolimus Pharmacokinetics in Chinese Pediatric Liver Transplant Patients

CYP3A5 genotypes affect tacrolimus pharmacokinetics and infectious complications in Chinese pediatric liver transplant patients.

Influence Ofcyp3a5genotypes on Tacrolimus Dose Requirement: Age and Its Pharmacological Interaction Withabcb1genetics in the Chinese Paediatric Liver Transplantation

Effect of cytochrome P450 3A5 (CYP3A5) genotype on tacrolimus dose requirement in renal transplant patients

Personalized Tacrolimus Dose Requirement by CYP3A5 but Not ABCB1 or ACE Genotyping in Both Recipient and Donor after Pediatric Liver Transplantation

Effect of CYP3A5 and MDR1 Gene Polymorphism in both Donor and Recipient on Concentration/Dose Ratios of Tacrolimus in Liver Transplant Patients

Association of CYP3A5 and C5 Polymorphisms with the Individual Dosage Regimen of Tacrolimus in Chinese Liver Transplantation Recipients During the Early Post-Transplantation Period

CYP3A4/5 genotypes and age codetermine tacrolimus concentration and dosage in pediatric heart transplant recipients

Combined Effect of Donor Cytochrome P450 3A Family Polypeptide 5 and Recipient Cytochrome P450 3A Family Polypeptide 4 Polymorphisms on the Individual Dosage Regimen of Tacrolimus in Chinese Liver Transplant Patients

Effect of CYP3A5 polymorphism on the concentration /dose ratio of tacrolimus in liver transplant recipients

Effect of CYP3A5 and MDR1 Gene Polymorphism on Concentration/Dose Ratios of Tacrolimus in Chinese Liver Transplant Patients

Impact of donor CYP3A5 genotype on pharmacokinetics of tacrolimus in South African paediatric liver transplant patients

Tacrolimus Dose Requirement In Relation To Donor And Recipient Abcb1 And Cyp3a5 Gene Polymorphisms In Chinese Liver Transplant Patients

Effect of CYP3A5 Genotype on Concentration and Efficacy of Tacrolimus in Patients with Kidney Transplantation

Influence Of Cyp3a5 Gene Polymorphisms Of Donor Rather Than Recipient To Tacrolimus Individual Dose Requirement In Liver Transplantation

Influence of CYP3A5*3 Genetic Polymorphism on Blood Concentration of Tacrolimus and Renal Function in Renal Transplant Recipients during the Stable Period

Influence of CYP3A5 polymorphism on tacrolimus blood concentrations in renal transplant patients

CYP3A5 Rather Than MDR1 Gene Polymorphism of Recipient is Related to Tacrolimus Individual Dose Requirement in Chinese Liver Transplant Patients

Effect of CYP3A5 Genotype on Renal Allograft Recipients Treated With Tacrolimus

CYP3A7, CYP3A4, and CYP3A5 genetic polymorphisms in recipients rather than donors influence tacrolimus concentrations in the early stages after liver transplantation.

A New Donors' Cyp3a5 and Recipients' Cyp3a4 Cluster Predicting Tacrolimus Disposition, and New-Onset Hypertension in Chinese Liver Transplant Patients